Toxicology Leadership Team
QPS Leadership Team
Vice President and Global Head of Safety Assessment and Regulatory Affairs
Dr. Walter Bee brings over 20 years of CRO and Pharma/Biotech experience in Preclinical Development to QPS. Prior to joining QPS in 2010, Dr. Bee was Vice President, Preclinical Development, at Halozyme, a biotechnology company in San Diego. Before, he held positions as Director of Toxicology, Pathology and Laboratory Animal Medicine at Johnson & Johnson on the West Coast and as Director of Toxicology at Scios Inc. At J&J/Scios, Dr. Bee supported toxicology/pathology of the portfolio, compound transitions, and life cycle management of drugs. He oversaw execution of preclinical plans and conduct of non-clinical safety/toxicology studies, directed developmental PK/ADME and bioanalytical plans. He also was a member of the J&J Global Preclinical Leadership Team. Dr. Bee has held positions at a number of leading Contract Research Organizations, including Covance (Münster, Germany), Sierra Biomedical/CRL (Reno, NV), and SNBL USA (Everett, WA), where he introduced numerous innovative in vivo toxicology and pharmacology methods and earned a status as an expert for reproductive toxicology and ocular toxicology. He earned his Ph.D. in Zoology in 1989 from the University of Münster, Germany.
Senior Director of Toxicology
Dr. Charlene Chen joined QPS in 2011; she is currently responsible for operation of the Center of Toxicology and Preclinical Sciences. Before joining QPS, Dr. Chen served as the Director of Toxicology facility in Development Center of Biotechnology (DCB), the first and largest preclinical CRO in Taiwan with over 20 years of history in preclinical testing. During her tenure as Managing Director in DCB, Dr. Chen was instrumental in obtaining the Department of Health (DOH) GLP compliance inspection approval and the certification of OECD GLP national compliance monitoring system. The team has complied 17 dossiers for US FDA submission since 2000. Dr. Chen has been involved with drug development of small molecules/biologics, herbal medicine and medical devices for 10 years. With the extensive toxicology knowledge from hands-on experience to regulatory issues, Dr. Chen has served as lecturer for numerous GLP and toxicology training courses and programs in Taiwan and published in peer-reviewed journals. She was the editor of the first edition of Chinese version of globally harmonized system for classification and labeling of chemicals (GHS) in 2006. Dr. Chen is well-versed in preparing IND submissions and designing studies to support clinical trials. Dr. Chen received her Sc.D. and MSPH from Tulane University, New Orleans, LA, USA.
Vice President of Operations
Mr. Andrew Nen joined QPS Taiwan in 2003 as Vice President of Operations. Prior to joining QPS Taiwan, he served as a Vice General Manager at Li Chang Investing Co., Ltd. and at Sagittarius Life Science Co., Ltd. where he was involved in IND filing and regulatory meetings with the DOH, as well as grant application with MOEA. Mr. Nen received his B.S degree and M.S. in pharmaceuticals from National Taiwan University.